North America Amniotic Products Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type [Amniotic Membranes (Cryopreserved Amniotic Membranes and Dehydrated Amniotic Membranes) and Amniotic Suspensions], Application (Wound Care, Orthopedics, Ophthalmology, and Other Applications), and End User (Hospitals & Clinics, Ambulatory Surgical Centers, and Other End Users) 

The North America amniotic products market is expected to grow from US$ 421.96 million in 2022 to US$ 689.98 million by 2028; it is estimated to grow at a CAGR of 8.5% from 2022 to 2028.

According to a 2018 retrospective examination of Medicare users, 8.2 million persons suffered wounds that were infected or not The acute and chronic wound treatments are estimated to cost between US$ 28.1 billion and US$ 96.8 billion by Medicare. Surgical wounds were the most expensive, followed by diabetic foot ulcers, with outpatient wound care costs higher than inpatient wound care. Traumatic wounds are a significant clinical, social, and economic burden because of the rising healthcare expenditures, increasing aging population, identification of difficult-to-treat infection risks such as biofilms, and the global hazard of diabetes and obesity.

 Traumatic wounds are those that have not proceeded through the normal healing process and have been open for longer than a month. These wounds have a variety of causes, all of which place a strain on the healthcare system. Diabetic and obese patients are at a higher risk of getting chronic wounds. Most persons who have a long-term open wound also have additional serious health problems. Comorbidities complicate chronic wounds, making it difficult to follow chronic wounds as a disease in and of itself. In comparison to the overall burden of chronic wounds as a health care concern, research funding dedicated to study chronic wounds is disproportionately low. Wound healing using amniotic membrane grafts has some therapeutic potential. Early use of an amniotic membrane for ulcers, burns, and cutaneous injuries proved therapeutic. Therefore, an increasing number of traumatic wounds is boosting the amniotic product market.

By introducing new features and technologies, vendors in the North America amniotic products can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the market growth at a good CAGR during the forecast period.

North America Amniotic Products Market Revenue and Forecast to 2028 (US$ Million)

North America Amniotic Products Market Segmentation

The North America amniotic products market is segmented on the basis of type, application, end user, and country. Based on type, the market is bifurcated into amniotic membranes and amniotic suspensions. The amniotic membranes segment dominated the market in 2022, and the market for this segment is expected to grow at the fastest pace during the forecast period. Based on application, the North America amniotic products market is segmented into wound care, orthopedics, ophthalmology, and other applications. The wound care segment dominated the market in 2022, whereas the market for the orthopedics segment is expected to grow at the fastest pace during the forecast period. Based on end user, the North America amniotic products market is segmented into hospitals and clinics, ambulatory surgical centers, and other end users. The hospitals and clinics segment dominated the market in 2022. However, the market for the ambulatory surgical centers segment is expected to grow at the fastest pace during the forecast period. Based on country, the North America amniotic products market is segmented into the US, Canada, and Mexico.

Integra LifeSciences; Katena Products. Inc.; Lucina BioSciences; MiMedx; NuVision Biotherapies Ltd; Organogenesis, Inc.; Sanuwave and Sanuwave Health, Inc.; Smith & Nephew; and Stryker are among the leading companies in the North America amniotic products market.